RT Journal Article
SR Electronic
T1 Docetaxel plus 5-Fluorouracil and Cisplatin (DCF) Induction Chemotherapy for Locally Advanced Borderline-resectable T4 Esophageal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3535
OP 3541
VO 31
IS 10
A1 TOMOYA YOKOTA
A1 SHUNZO HATOOKA
A1 TAKASHI URA
A1 TETSUYA ABE
A1 DAISUKE TAKAHARI
A1 KOHEI SHITARA
A1 MOTOO NOMURA
A1 CHIHIRO KONDO
A1 AYAKO MIZOTA
A1 YASUSHI YATABE
A1 MASAYUKI SHINODA
A1 KEI MURO
YR 2011
UL http://ar.iiarjournals.org/content/31/10/3535.abstract
AB Background: This study aimed to evaluate the efficacy of docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Patients and Methods: We retrospectively analyzed data regarding thirty patients with borderline-resectable T4 tumor who received either DCF or cisplatin plus 5-fluorouracil (FP) as induction chemotherapy. Results: The overall response rate was significantly better for the DCF group than the FP group. In the DCF group, 6/16 patients achieved a grade 2 histological post-chemotherapeutic effect after treatment, compared to 1/14 in FP group. Except for myelotoxicity, no other significant differences in toxicity were observed during induction chemotherapy between groups. The DCF regimen did not result in increased postoperative complications compared to the FP regimen. Postoperative recurrence or distant metastasis was observed in 7/10 of FP patients and 5/12 of DCF patients. Conclusion: DCF induction chemotherapy may be an option for conversion therapy of initially unresectable, locally advanced esophageal cancer.